This could potentially alter chromatin conformation and result in a shift in the promoter usage from the strongest/canonical one to the weak/alternative promoter, decreasing DMPK expression levels in DM1 myogenic samples. This evidence concerns the gene DMPK and myotonic dystrophy type 1.